newsfilter
← Earnings
Earnings Releases·

Aclaris Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue decreased to $1.5 million for the quarter and $5.1 million year-to-date in 2026, down from $3.3 million and $6.5 million respectively in the prior year period due to the absence of a prior-year sales milestone; net loss widened to $18.5 million for the quarter and $59.8 million year-to-date.
  • Cash and marketable securities increased to $204.6 million as of September 30, 2026, following a $50.0 million equity raise in October 2026, providing sufficient funding for operations through the first half of 2029.
  • Clinical development expenses rose significantly to $16.1 million for the quarter and $49.8 million year-to-date, driven by manufacturing and clinical costs for ATI-052 and preclinical costs for ATI-9494.
  • The company expects top-line Phase 2 ADMIRATION trial results for bosakitug in Q4 2026, initiation of a Phase 2b modzatinib trial in Q4 2026, and an IND filing for ATI-9494 in Q4 2026.
Company
ACLARIS THERAPEUTICS INC
Sector
Healthcare
Industry
Diagnostics & Research